GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (STU:GPH) » Definitions » EV-to-FCF

Galmed Pharmaceuticals (STU:GPH) EV-to-FCF : -14.45 (As of Jun. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Galmed Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Galmed Pharmaceuticals's Enterprise Value is €83.95 Mil. Galmed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-5.81 Mil. Therefore, Galmed Pharmaceuticals's EV-to-FCF for today is -14.45.

The historical rank and industry rank for Galmed Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:GPH' s EV-to-FCF Range Over the Past 10 Years
Min: -19.57   Med: -0.14   Max: 7.38
Current: 1.69

During the past 12 years, the highest EV-to-FCF of Galmed Pharmaceuticals was 7.38. The lowest was -19.57. And the median was -0.14.

STU:GPH's EV-to-FCF is ranked better than
58.94% of 397 companies
in the Biotechnology industry
Industry Median: 6.4 vs STU:GPH: 1.69

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-25), Galmed Pharmaceuticals's stock price is €4.86. Galmed Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.000. Therefore, Galmed Pharmaceuticals's PE Ratio for today is N/A.


Galmed Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Galmed Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals EV-to-FCF Chart

Galmed Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.15 -0.59 -0.34 0.05 1.68

Galmed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.42 1.17 1.68 1.39

Competitive Comparison of Galmed Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Galmed Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's EV-to-FCF falls into.



Galmed Pharmaceuticals EV-to-FCF Calculation

Galmed Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=83.952/-5.809
=-14.45

Galmed Pharmaceuticals's current Enterprise Value is €83.95 Mil.
Galmed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galmed Pharmaceuticals  (STU:GPH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Galmed Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.86/0.000
=N/A

Galmed Pharmaceuticals's share price for today is €4.86.
Galmed Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Galmed Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Galmed Pharmaceuticals (STU:GPH) Business Description

Traded in Other Exchanges
Address
16 Tiomkin Street, Tel Aviv, ISR, 6578317
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Galmed Pharmaceuticals (STU:GPH) Headlines

No Headlines